Latest immunotherapy news
Perioperative Enfortumab Vedotin + Pembrolizumab Tied to Improved Outcomes With Bladder Cancer
posted February 27th
by modernClinician Editorial Team
by modernClinician Editorial Team
Guidelines Issued for Management of Acute Lymphoblastic Leukemia in Teens, Young Adults
posted February 23rd
by modernClinician Editorial Team
by modernClinician Editorial Team
Immunochemotherapy Infusions Early in the Day Tied to Improved NSCLC Survival
posted February 12th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Quadruplet Regimen for Adults With Newly Diagnosed Multiple Myeloma
posted February 4th
by modernClinician Editorial Team
by modernClinician Editorial Team
Editor's Recommendations
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC 
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors 
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer 
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment Related Articles
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine 
Indefinite-Duration Maintenance Therapy No Better Than Fixed-Duration Therapy in Multiple Myeloma 
Rituximab Noninferior to Ocrelizumab for Newly Diagnosed Relapsing MS 
Aglatimagene Besadenovec + Valacyclovir Ups DFS in Localized Prostate Cancer Monthly Specialist Briefings
Stay Connected
